MENU
+Compare
CARA
Stock ticker: NASDAQ
AS OF
Apr 3 closing price
Price
$4.95
Change
-$0.15 (-2.94%)
Capitalization
22.5M

CARA Cara Therapeutics Inc Forecast, Technical & Fundamental Analysis

Cara Therapeutics Inc is a development-stage biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus... Show more

Industry: #Biotechnology
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for CARA with price predictions
Apr 02, 2025

CARA's RSI Oscillator recovers from overbought zone

The 10-day RSI Oscillator for CARA moved out of overbought territory on March 24, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 instances where the indicator moved out of the overbought zone. In of the 26 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on March 31, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CARA as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CARA turned negative on March 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CARA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CARA broke above its upper Bollinger Band on March 21, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

CARA moved above its 50-day moving average on April 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CARA crossed bullishly above the 50-day moving average on March 18, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CARA advanced for three days, in of 270 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 114 cases where CARA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CARA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.113) is normal, around the industry mean (13.260). P/E Ratio (0.000) is within average values for comparable stocks, (64.931). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.878). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (3.146) is also within normal values, averaging (252.036).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CARA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
CARA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

CARA is expected to report earnings to fall 11.11% to -23 cents per share on November 29

Cara Therapeutics Inc CARA Stock Earnings Reports
Q3'24
Est.
$-0.24
Q2'24
Missed
by $0.01
Q1'24
Missed
by $0.16
Q4'23
Missed
by $0.14
Q3'23
Est.
$-0.52
The last earnings report on August 05 showed earnings per share of -27 cents, missing the estimate of -25 cents. With 23.45K shares outstanding, the current market capitalization sits at 22.50M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Atlantic Street
Phone
+1 203 406-3700
Employees
55
Web
https://www.caratherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OMH2.420.19
+8.52%
Ohmyhome Limited
BCML24.08-1.64
-6.38%
BayCom Corp
ZS192.21-14.83
-7.16%
Zscaler
PEBO27.55-2.27
-7.61%
Peoples Bancorp
HWC47.53-5.44
-10.27%
Hancock Whitney Corp

CARA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, CARA has been loosely correlated with CYCC. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if CARA jumps, then CYCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CARA
1D Price
Change %
CARA100%
-3.53%
CYCC - CARA
61%
Loosely correlated
-6.20%
CKPT - CARA
47%
Loosely correlated
+0.25%
GPCR - CARA
41%
Loosely correlated
-3.48%
AXON - CARA
37%
Loosely correlated
-3.35%
FBIO - CARA
32%
Poorly correlated
-5.59%
More